This study focuses on women with female infertility, specifically those with low ovarian reserve. The research examines the effectiveness of platelet-rich plasma with growth factors (PRGF-Endoret®) compared to placebo in improving outcomes during in vitro fertilization (IVF) treatment. Platelet-rich plasma is a concentrated portion of blood that contains special proteins that help with healing and tissue growth.

The treatment involves an intraovarian injection (injection directly into the ovary) of either platelet-rich plasma with growth factors or a placebo consisting of sodium chloride solution (salt water). The main purpose is to determine if this treatment can increase the number of eggs retrieved during the IVF procedure in women with reduced ovarian function.

During the study, participants will undergo one IVF cycle where they will receive a single injection of either the study treatment or placebo. The maximum amount of solution injected will be 6 milliliters, and the treatment will be administered through a standard injection procedure. The study will measure how many eggs can be collected following the treatment.